Innovative drugs are rapidly debuting in China, with new targets, new mechanisms, and new therapies accelerating their influx into the Chinese market.

Recently, an innovative drug for a rare disease made its debut in China, garnering widespread attention. This is not an isolated incidentsince the beginning of this year, multiple innovative drugs from multinational pharmaceutical companies have been launched in China first. At the same time, globally innovative drugs from local enterprises such as Bai Li Tianheng and Keji Pharmaceuticals have also been densely introduced. Both multinational giants and local companies have coincidentally chosen China as their launch site, completely rewriting the decades-old pattern of first Europe and America, then China. "China first" has become the norm, and innovative drugs are emerging as dark horses in our country's new triad. Behind this wave of initial launches is a rapid accumulation of new targets, mechanisms, and therapies converging in China, as the Chinese innovative drug industry transitions from global participant to global leader.